Can Zenas BioPharma’s (ZBIO) Clinical Pipeline Justify Its Heavy Cash Burn?

This is a summary. Read the complete story at Yahoo Finance below.

Related Stories

marketsabout 9 hours ago

Elon Musk opens the door for a big SpaceX acquisition

The rocket and satellite-internet company is looking to challenge telecom giants.

MarketWatch

marketsabout 9 hours ago

Data centers run on debt. That was a problem for bonds this year — and it’s only going to get worse.

AI debt issuance this year overwhelmed investor portfolios, and has disappointed from a performance perspective. The funding need won’t get any better with Democrats in control of Congress.

MarketWatch

marketsabout 9 hours ago

Micron’s stock is dirt cheap — and that’s igniting a fierce online debate

Valuation purists see a ridiculously inexpensive stock, but some semiconductor investors say Micron’s earnings power won’t hold up.

MarketWatch